TIDMOXB
RNS Number : 5117M
Oxford Biomedica PLC
07 May 2015
Oxford BioMedica Annual General Meeting
London, UK - 7 May 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, announces today that all resolutions proposed were
duly passed at its Annual General Meeting (AGM), held today in
London.
In accordance with Listing Rule 9.6.18 the following resolutions
are those which were passed at the meeting concerning special
business:
-- Resolution 14: to empower the Directors to allot equity
securities for cash, pursuant to section 570 of the Companies Act
2006 as if section 561 of the Companies Act 2006 did not apply to
such allotment, up to an aggregate nominal amount of 5 per cent. of
the presently issued shares; and
-- Resolution 15: to permit the Group to convene general
meetings (other than annual general meetings) on not less than 14
days' notice.
The full text of all the resolutions can be viewed in the Notice
of Meeting by visiting the Group's website at
www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above
resolutions passed at the 2015 AGM have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are
shown below. On the Record Date (5 May 2015) there were
2,568,040,015 1p ordinary shares in issue, each carrying one vote
per share.
Votes
Votes at
at other Total
Votes Chairman's proxy Votes Votes votes
Resolution For Discretion Discretion Against Withheld cast Result
------------- --------------- ------------ ------------ ----------- ----------- ---------------- ---------
Ordinary resolutions
1 1,569,855,529 997,910 3,429,924 44,395 37,743 1,574,365,501 Passed
2 1,568,499,344 1,124,976 3,429,924 1,144,667 166,590 1,574,365,501 Passed
3 1,559,509,773 1,151,115 3,429,924 2,231,914 8,042,775 1,574,365,501 Passed
4 1,565,366,633 998,823 3,429,924 4,512,371 45,191 1,574,352,942 Passed
5 1,565,363,916 998,823 3,429,924 4,513,033 47,246 1,574,352,942 Passed
6 1,565,365,962 998,823 3,429,924 4,503,033 55,200 1,574,352,942 Passed
7 1,565,355,486 996,203 3,429,924 4,512,371 58,958 1,574,352,942 Passed
8 1,569,730,217 1,000,773 3,429,924 116,408 88,179 1,574,365,501 Passed
9 1,559,704,929 1,052,832 3,429,924 2,148,027 8,029,789 1,574,365,501 Passed
10 1,561,084,685 1,108,626 3,429,924 846,210 7,896,056 1,574,365,501 Passed
11 1,561,001,842 1,068,751 3,429,924 966,478 7,898,506 1,574,365,501 Passed
12 1,569,491,544 1,060,845 3,429,924 190,709 192,479 1,574,365,501 Passed
13 1,569,481,603 1,057,412 3,429,924 249,740 146,822 1,574,365,501 Passed
Special resolutions
14 1,568,482,462 1,155,736 3,429,924 1,090,080 207,299 1,574,365,501 Passed
15 1,566,284,325 1,208,555 3,429,924 3,313,737 128,960 1,574,365,501 Passed
The following resolution was taken on a poll called by the
Chairman of the Company at the meeting:
-- Resolution 15: to permit the Group to convene general
meetings (other than annual general meetings) on not less than 14
days' notice.
The results of the votes cast were as follows:
Votes For Votes Against Votes Withheld Total Votes Result
Cast
-------------- -------------- --------------- -------------- -------
1,583,347,994 6,562,802 7,731,340 1,589,910,796 Passed
-------------- -------------- --------------- -------------- -------
The number of votes validly cast in relation to Resolution 15
was 1,589,910,796, which constitutes 61.91% of the issued share
capital of the Company.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk .
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSSUFFWFISEII
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024
